Overview of Covid 19 and Unani formulation Tiryaq-e-Wabai
Coronavirus disease 2019 (COVID-19) is arguably the biggest health crisis the world has faced in 21st century. It is an infectious disease and declared pandemic by the World Health Organization. It is a pandemic disease of modern time with unique and rapid transmission rate and affected almost all the nations without respecting any border. It’s a novel infection which is caused by SARS CoV-2 with Serious Clinical manifestation i.e. Fever, Cough, Cold, Respiratory distress further may result into Death. There is no definite therapeutic drug or vaccine available for COVID-19 so far despite numerous series of experimental and clinical research. Research is in progress on therapeutic efficacy of various agents including antimalarials (Chloroquine and Hydroxychloroquine), antiviral drugs, and convalescent serum of recovered patients. Unani system of medicine is one of the traditional systems of medicine which is being explored for providing preventive, supportive and rehabilitative care to patients. Unani system of medicine has a detailed description of drugs that are utilized in many infectious diseases, including respiratory infections. Immune response is essential to eliminate virus and to preclude disease progression to severe stages. Therefore, strategies to boost immune response are certainly important. Therefore, it is important to summarize the evidence regarding the preventive measures, control options such as immunostimulator and prophylactic treatment in Unani medicine against Covid- 19. This review summarizes various pharmacological actions of Unani formulation Tiryaq e wabai in unani literature and various reported pharmacological activities which can possibly provide prevention, control and reduction of complications of this deadly disease.
Keywords: Unani medicine, Covid 19, immune response, Tiryaq e Wabai
2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020.
3. Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 20th ed. New York: McGraw Hill education, 2019; 535
4. Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, Ganesan S, Venugopal A, Venkatesan D, Ganesan H, Rajagopalan K. COVID-19: A promising cure for the global panic. Science of the Total Environment, 2020 Apr 4: 138277
5. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care, 2020 Mar 10.
6. Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus, 2020 Apr; 12(4).
7. Rocklöv J, Sjödin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. Journal of travel medicine, 2020 Feb 28.
8. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q. Coronavirus infections and immune responses. Journal of medical virology, 2020 Apr; 92(4):424-32.
9. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clinical Rheumatology, 2020 Apr 10: 1.
10. Kabiruddin-HM. Hummiyat-e-Qanoon New Delhi: CCRUM, 2009.
11. Khan MA. Al-Akseer (Urdu transalation by kabeeruddin M). Vol 2. New Delhi: Ejaz publication house, 2003; 916-20
12. Khan MA. Al-Akseer (Urdu transalation by kabeeruddin M). Vol 2. New Delhi: Ejaz publication house, 2003; 916-20.
13. Razi ABMBZ. Al-Hawi (Urdu Translation by CCRUM). Vol 15. New Delhi; CCRUM, Ministry of Health and family welfare, Govt. of India, 2002; 12-22.
14. Khan MA. Al-Akseer (Urdu transalation by kabeeruddin M). Vol 2. New Delhi: Ejaz publication house, 2003; 916-20.
15. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MARS and novel coronavirus(COVID-19) epidemics. The newest and biggest global health threats: what lessons have we learned? International journal of epidemiology, 2020; feb 22.
16. Arzani, M. Akbar. Tibb-e-akbar(Urdu translation by hakeeem M. Hussain), IdaraKitab-u- Shifa, kuchaChalan New Delhi, P.6 72-74.
17. 22. Sahin AR, Erdogan A, Agaoglu PM, Dineri Y, Cakirci AY, Senel ME, OKyay, Tasdogan AM. 2019 Novel Coronavirus(COVID-19) Outbreak: A Review of
theCureent Literature. EJMO, 2020; 4(1): 1-7.
18. Ismail J. Vol. 5. New Delhi: Kitab al Shifa; 2010. Zakhirakhuarzamshahi; p. 94.
19. Kabeeruddin M. Lahore: Siddiqui Publications; 1921. BayazeKabeer; p. 12. 36.
20. Moss RW. New York: Equinox Press; 1996. Cancer Therapy-The Independent Consumer Guide to Non-toxic Treatment and Prevention; pp. 126–7.
21. Singh S, P.K. Sharma N, Kumar R. Dudhe Biological activities of Aloe vera. Int J Pharm Technol. 2010;l2:259–80.
22. Hamman JH. Composition and applications of Aloe vera leaf gel. Molecules. 2008;13:1599–616.
23. Assimopoulou AN, Zlatanos SN, Papageorgiou VP. Anti-oxidant activity of natural resins and bio-active triterpenes in oil substrates. Food Chem. 2005;92:721–7.
24. Bakshi H, Sam S, Islam T, Singh P, Sharma M. The free radical scavenging and the lipid peroxidation inhibition of crocin isolated from Kashmiri saffron (Crocus sativus) occurring in northern part of India International Journal of PharmTech Research CODEN (USA) IJPRIF. 2009;1:1317–21.
25. Nigar Z, Itrat M. Evaluation of a Unani polyherbal formulation (Tiryaqewabai) as an immunostimulator in elderly persons. Anc. Sci. Life, 33 (2013), p. 117,
26. Anonymous (2009). The Unani Pharmacopoeia of India, Part I, Vol. VI, Govt. of India, Ministry of Health & Family Welfare, Department of AYUSH, New Delhi, pp. 101,102.
27. Anonymous (2007). The Unani Pharmacopoeia of India, Part I, Vol. I, Govt. of India, Ministry of Health & Family Welfare, Department of AYUSH, New Delhi pp. 82,83
28. Anonymous (2007). The Unani Pharmacopoeia of India, Part I, Vol. II, Govt. of India, Ministry of Health & Family Welfare, Department of AYUSH, New Delhi pp. 77-78
29. IbnBaitar. Al-Jami Li-Mufradat al Adviawa al Aghzia New Delhi: CCRUM; 1999: p. 51-54; 170-175.,
30. Anonymous. The Unani Pharmacopoeia of India, New Delhi: AYUSH; 2007: p. 30,14
31. Nadkarni KM. Indian MateriaMedica. 3rd ed. Mumbai: Popular Prakashan Private Limited; 2010: p. 73-74, 376.
32. Ibrahim A. Kitab Al- Fatah fi al Tadawi (Urdu Translation by Hkm Abdul Bari). First Edition ed. Delhi: NCPC Printers; 2007: p. 166-167; 188-189.
33. Ghani MN. KhazayinulAdvia New Delhi: IdaraKitabulShifa; p. 308-312, 814-815.
34. Kabeeruddin H. MakhzanulMufradat (Kitab al Advia). 2nd ed. New Delhi: IdaraeKitabulShifa; 2007: p. 259-260
35. Sina I. Al-Qanoonfil-tib Lahore: Matbo'aateSulemani; 1998:163- 164, p. 188-189.
36. QarabadeenMajeedi Delhi: All India Unani Tibbi Conference; 1986: p. 21,51,53,71,84,95,176,288,347,353
37. Chatterjee P, Chakraborty B, NANDY S. Aloe vera Plant: Review with significant Pharmacological Activities. Mintage Journal of Pharmaceutical and Medical Sciences. 2013; p. 21-24.,
38. Bautista-Pérez R, Segura-Cobos D, Vázquez-Cruz B. In vitro Antibradykinin Activity of Aloe barbadensis gel. Journal of Ethnopharmacology. 2004; 93:89–92.,
39. Nwanjo HU. Antioxidant activity of the exudate from Aloe barbadensis leaves in diabetic rats. BIOKEMISTRI. 2006; 18(2):77-81.,
40. Afzal, Ali M, Hassan RAH, Sweedan N, Dhami MSI. Identification of some prostanoids in Aloe vera extracts. Planta Med. 1991; 57:38-
41. Effect 49. Chandu AN, Kumar SC, Bhattacharjee C, Debnath S. Studies on immunomodulatory activity of Aloe vera (Linn). International Journal of Applied Biology and Pharmaceutical Technology. 2011; 2(1):19-22. 50
42. Ognik K, Sembratowicz I. Effect of Aloe-plus preparation supplement on hematological and immunological blood parameters and performance of turkey hens. Turk. J. Vet. Anim. Sci. 2012; 36(5):491-498.
43. Anonymous. 2009. The Unani pharmacopoeia of India, Part I vol. VI, Govt of India, Ministry of Health & family welfare, pp.101,102
44. Hosseinzadeh H, Ghenaati J. Evaluation of the antitussive effect of stigma and petals of saffron(Crocus sativus)and its components, safranal and crocin in guinea pigs. Fitoterapia. 2006; 77:446–8.,
45. Abdullaev FI, Riverón-Negrete L, Caballero-Ortega H, Manuel Hernández J, Pérez-López I, Pereda-Miranda R, et al. Use of in vitro assays to assess the potential antigenototoxic and cytotoxic effect of saffron (Crocus sativus) Toxicol In Vitro. 2003; 17:731–6.,
46. Hosseinzadeh H, Younesi H. Petal and stigma extracts of Crocus sativus L. have antinoceceptive and anti-inflammatory effects in mice. BMC Pharmacol. 2002;2:7
47. Khare CP. Indian Medicinal Plants. New Delhi: Springer India (P) Ltd; 2007; 72:73, 79,
48. Nadkarni KM. Indian Plants and Drugs. 1st ed. New Delhi: Shrishti Book Distributors; 2004; 49:14.
49. Ghani N. Khazainul Advia.3rd ed. New Delhi: IdaraeKitabulShifa; 2011: 287, 813-14, 1229-30, 1276-77.
50. Bentley R, Trimen H. Medicinal Plants. Vol I. New Delhi: Om sons Publications; 2002: 322-25, 327-28.,
51. Prajapati ND, Kumar U. Agro’s dictionary of Medicinal Plants. 2nd ed. Jodhpur: Agrobios (India); 2005: 90
52. Betar I. Al-JamiulMufaradatulAdviaWa Al-Aghziya. Vol IV. 2nd ed. New Delhi: CCRUM; 2003: 316-,
53. Ghani N. Khazainul Advia.3rd ed. New Delhi: IdaraeKitabulShifa; 2011: 287, 813-14, 1229-30, 1276-77. 15.
54. Rafiquddin M. KanzulAdviaMufrada. 1st ed. Aligarh: University Publication Unit; 1985: 123-24, 415, 631-32.
55. Hanus LO, Rezunka T, Dembitsky VM, Moussaieff A. Myrrh-Commiphorachemistery. Biomed Papers 2005; 149(1):3-28
56. Ahmed IS, Tohami MSE, Almagboul AZ, Verpoorte R. Quercetin and β-sitosterol from CommiphoramyrrhaFum Extracts. University of Africa Journal of Sciences
57. Mahboubi M, Kashani LMT. The anti-dermatophyte activity of Commiphoramolmol. Pharm Biol 2016; 54(4):720-25
58. Z. Nigar, M. Itrat. Evaluation of a Unani polyherbal formulation (Tiryaqewabai) as an immunostimulator in elderly persons. Anc. Sci. Life, 2013; 33:117, 10.4103/0257-7941.139054
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).